Houston Methodist in The Woodlands has a $10 million infusion. Rendering courtesy of Houston Methodist

Houston Methodist has been in the spotlight of late, notably, the healthcare system was ranked No. 1 in Texas for a third year in a row — and one of the top in the nation — in May.

Now, the system has just received an large donation that will help bring the award-winning prescription for success north. Houston Methodist has been gifted a $10 million philanthropic commitment specifically for its medical expansion into The Woodlands, the hospital announced.

Thanks to the gift from an anonymous donor, this is the first time a Texas Medical Center institution will offer a sponsored academic medical program specifically at one of its community hospitals, Methodist notes in press materials. This program will include fellowships in cardiovascular disease, orthopedic surgery, pulmonary critical care, and sports medicine, and more.

This philanthropic offering marks the largest gift Houston Methodist The Woodlands Hospital, or any of the regional hospital within the Houston Methodist system, has ever received.

“Building a well-rounded graduate medical education program has always been a priority for Houston Methodist,” said Timothy Boone, M.D., Ph.D., Director of the Education for the Houston Methodist Academic Institute, in a statement. “By creating an academic medical campus housed at a regional hospital where patients can seek specialty care typically only offered in the Texas Medical Center, we’re extending the academic culture and patient offerings in The Woodlands beyond standard clinical care. We’ll also have the opportunity to advance scholarly activity with our faculty and staff who will be part of training these residents and fellows and to bring highly specialized offerings to a booming area of the city.”

Specifically, Houston Methodist’s academic medical program includes more than 350 residents and fellows. Those who are a part of the new academic program, slated to launch in 2024, at Houston Methodist The Woodlands, will match and serve their full time residency training in internal medicine, and potentially their fellowship training, in The Woodlands and the Medical Center.

“The generosity and encouragement from this anonymous donor is a testament to the exceptional work our physicians and staff in The Woodlands provide day in and day out,” said Debra Sukin, regional senior vice president and CEO of Houston Methodist The Woodlands. “This commitment will help open multiple doors — to attract some of the best new physicians, to retain well-trained specialists who want to further their medical expertise through fellowships and hopefully want to grow their practice in a vibrant community that’s also a wonderful area to live. We’re humbled to have this support and excited about the opportunity to grow our academic medical education offerings on the north side of Houston.”

------

This article originally ran on CultureMap.

Reliant and Aramco Americas have provided Houston Methodist funds to move forward pertinent research and opportunities. Courtesy of Methodist Hospital/Facebook

2 corporations write checks to go toward Houston hospital's COVID-19 efforts

money moves

Two Houston companies have doled out cash to a Houston hospital's efforts in driving innovation during the pandemic as well as moving forward in a post-COVID-19 world.

Houston Methodist received $500,000 from Houston-based Aramco Americas and $130,000 from Houston-based Reliant. Aramco's gift will go toward funding ongoing research on convalescent plasma therapy as a treatment for COVID-19 and Reliant's donation will create the Reliant Innovation Fund.

"The challenges that we have and will continue to face with the COVID-19 pandemic amplifies the need for fresh ideas to combat this disease and treat those who have been affected," says Dr. Faisal Masud, medical director of the Center for Critical Care at Houston Methodist Hospital, in a news release from Reliant. "Innovating is at the core of what we do at Houston Methodist, and this generous gift from Reliant will make a difference for patients both now and for years to come."

According to the release, $100,000 will go toward supporting students in the Texas A&M University's Engineering Medicine program, which combines engineering and medical courses to allow for students to receive a master's in engineering and a medical degree in four years. Currently, A&M is renovating a building in the Texas Medical Center that will be the future home of the program.

"The EnMed program is educating a new type of physician — one with an engineering background and a forward-thinking, innovative medical mindset. Reliant's partnership and donation will allow our students to innovate for the dynamic needs on today's clinical front lines," says Dr. Timothy Boone, director of the Houston Methodist Education Institute and Associate Texas A&M Dean, in the release.

The other $30,000 of Reliant's gift will go towards expanding the hospital's patient-centric mobile app, CareSense, which Houston Methodist has used to connect with COVID-19 patients after they have left the hospital.

Aramco's donation will be used to support Houston Methodist's plasma research on COVID-19 treatment. The hospital was the first academic medical center in the United States to get FDA approval for this type of treatment on COVID-19 patients.

"Convalescent plasma therapy has been effective in other infectious diseases and our physician-scientists are working to develop it into a first-line treatment for COVID-19," says Dr. Dirk Sostman, president at the Houston Methodist Academic Institute, in a news release from Aramco.

The treatment collects blood from recovered COVID-19 patients and infuses the plasma into currently ill COVID-19 patients in hopes that the recovered patient's plasma can provide the antibodies for the ill patient to fight off the disease.

"Houston Methodist Hospital is a world-leader in healthcare as well as research and development," says Mohammad S. Alshammari, president and CEO of Aramco Americas in the release. "Our donation is an opportunity to support the innovative work occurring there in support of the Houston community and to contribute to long-term medical solutions for this global health crisis."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”